On October 31, the Centers for Medicare & Medicaid Services (CMS) issued a final rule announcing changes for Medicare payments under the Physician Fee Schedule (PFS), effective on or after January 1, 2026.
Health Care Practice Leader Douglas Grimm was quoted in a recent article discussing the rising popularity of joint operating agreements (JOAs) among health systems facing industry pressures.
The US Food and Drug Administration (FDA) regulates the products hospitals and health systems use, make, or study. As health system innovations increasingly leap quickly across service lines, regulatory obligations can shift in real time.
ArentFox Schiff has been awarded 62 top rankings in the 2026 edition of Best Law Firms®, which recognizes firms for professional excellence based on consistently positive ratings from clients and peers.
Last week’s jury convictions of Safe Chain Solutions’ co-owners in United States v. Brosius, No. 1:24-cr-20255 (S.D. Fla.) coupled with US Food and Drug Administration (FDA) Drug Supply Chain Security Act (DSCSA) enforcement make one conclusion unavoidable: The DSCSA is both a regulatory mandate and a criminal risk boundary.
Join AFS Life Sciences Partner Stephanie Trunk and Darshan Kulkarni, Life Sciences regulatory and compliance attorney, to unpack the recent acceleration of mergers and acquisitions across the life sciences sector.
Health Care Practice Leader Douglas Grimm was quoted on the increasingly complex legal protocols hospitals must navigate following the rollback of a Biden-era policy restricting immigration enforcement in hospitals.
On August 18, the US Court of Appeals for the Federal Circuit issued a significant decision in King v. United States, affirming that reductions in multiemployer pension benefits authorized by the Multiemployer Pension Reform Act of 2014 (MPRA) are not takings under the Fifth Amendment.
Health Care Partner David Greenberg will present in a BARBRICLE course titled “Overpayment Recoveries by Health Insurers: Bringing and Defending Claims, Evaluating Merits, Scope of Recovery” on October 1, 2025.
Earlier this month, the US Department of Health and Human Services (HHS) and US Food and Drug Administration (FDA) announced a nationwide crackdown on direct-to-consumer (DTC) drug advertisements.
Following nearly two years of litigation, Cigna Health and Life Insurance Company and the named plaintiffs in Hecht v. Cigna Health and Life Insurance Co., Case No. 1:24-cv-05926 (N.D. Ill.) have announced a class action settlement in principle.
Gayland Hethcoat was featured in a Law360 Healthcare AuthorityQ&A on how the One Big Beautiful Bill Act (OBBBA) legislation is expected to significantly reduce state-directed payments in Medicaid managed care programs and impact hospitals, nursing facilities, and patients.
Investigations Partners Hillary Stemple and Nadia Patel will host a CLE webinar on how health care organizations’ compliance officers and general counsel can bolster compliance mechanisms in light of the re-launch of the Department of Justice and Department of Health and Human Services’ False Claims Act (FCA) Working Group.
The Medicaid Drug Rebate Program (MDRP) Summit 2025 will be held in Chicago, IL, from September 15-17, 2025. This hybrid event is hosted by Informa Connect and will feature topics such as 340B, drug pricing policy, and the Inflation Reduction Act (IRA), designed to aid attendees in mastering complex regulatory guidelines.